Genetic Technologies Valuation
| GTG Stock | 0.04 0.00 0.00% |
Genetic Technologies seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Genetic Technologies from evaluating the firm fundamentals such as Return On Equity of -1.85, return on asset of -0.63, and Current Valuation of 5.53 M as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 3.0984 | Enterprise Value 5.5 M | Enterprise Value Ebitda (4.37) | Price Sales 0.5863 | Enterprise Value Revenue 0.7091 |
Overvalued
Today
Please note that Genetic Technologies' price fluctuation is out of control at this time. Calculation of the real value of Genetic Technologies is based on 3 months time horizon. Increasing Genetic Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Genetic Technologies' intrinsic value may or may not be the same as its current market price of 0.04, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.039 | Real 0.0336 | Hype 0.04 | Naive 0.04 |
The intrinsic value of Genetic Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Genetic Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Genetic Technologies helps investors to forecast how Genetic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genetic Technologies more accurately as focusing exclusively on Genetic Technologies' fundamentals will not take into account other important factors: Genetic Technologies Cash |
|
Genetic Technologies Total Value Analysis
Genetic Technologies is currently forecasted to have takeover price of 5.53 M with market capitalization of 5.67 M, debt of 875.19 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genetic Technologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.53 M | 5.67 M | 875.19 K |
Genetic Technologies Investor Information
The book value of the company was currently reported as 0.01. The company had not issued any dividends in recent years. Genetic Technologies had 1:100 split on the 14th of December 2023. Based on the key indicators related to Genetic Technologies' liquidity, profitability, solvency, and operating efficiency, Genetic Technologies is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Genetic Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genetic Technologies has an asset utilization ratio of 123.89 percent. This implies that the Company is making USD1.24 for each dollar of assets. An increasing asset utilization means that Genetic Technologies is more efficient with each dollar of assets it utilizes for everyday operations.Genetic Technologies Ownership Allocation
Genetic Technologies has a total of 145.42 Million outstanding shares. Genetic Technologies retains 5.56 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genetic Technologies Profitability Analysis
The company reported the revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M.About Genetic Technologies Valuation
The stock valuation mechanism determines Genetic Technologies' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Genetic Technologies based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Genetic Technologies. We calculate exposure to Genetic Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genetic Technologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.9 M | 3.8 M |
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.